Dr. Oki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd Unit 429
Houston, TX 77030Phone+1 713-563-6705
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2003 - 2006
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2000 - 2003
Graduate School of Medicine and Faculty of Medicine, The University of TokyoClass of 1998
Certifications & Licensure
TX State Medical License 2010 - 2026
CA State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Start of enrollment: 2003 Sep 01
- SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2008 Nov 01
- Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 390 citationsBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s LymphomaJoseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won Kim
The New England Journal of Medicine. 2017-12-10 - 537 citationsResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, Xuelin Huang, Susan O'Brien
Blood. 2007-01-01 - 41 citationsEpigenetic Mechanisms in AML – A Target for TherapyYasuhiro Oki, Jean Pierre J. Issa
Cancer Treatment and Research. 2009-01-01
Journal Articles
- Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II StudyFrancesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
Abstracts/Posters
- Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...Yasuhiro Oki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Tenalisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
